1. INVO Fertility acquires Family Beginnings, enhancing its clinic presence. 2. Family Beginnings generated $1.2M revenue, indicating potential growth. 3. Transaction scheduled to complete by February 2026, subject to conditions. 4. The acquisition aims to improve access to fertility care and services. 5. INVOcell device offers a cost-effective alternative to traditional IVF.
FAQ
Why Bullish?
Acquisitions typically indicate growth potential, expanding market presence. Historical acquisitions in healthcare often lead to increased stock values.
How important is it?
The acquisition supports market expansion and increased service offerings, impacting investor sentiment.
Why Long Term?
While acquisition impacts will unfold over time, enhanced services and access can significantly increase revenues long-term.
INVO Fertility Signs Agreement to Acquire Family Beginnings Fertility Clinic
SARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF), a leading healthcare company dedicated to the establishment and operation of fertility clinics, has officially signed a purchase agreement to acquire Family Beginnings, P.C. This prominent fertility clinic serves patients in Indiana and the wider Midwest, marking a significant step in INVO's strategy to enhance its network of fertility care centers across the United States.
Details of the Acquisition
The definitive purchase agreement represents a pivotal milestone following INVO’s announcement on November 27, 2025, regarding its intent to proceed with this acquisition. Family Beginnings reported revenues of approximately $1.2 million with a net income of around $0.2 million for the trailing 12-month period ending September 30, 2025.
Steve Shum, CEO of INVO, expressed enthusiasm about the acquisition, stating, “We are pleased to move forward with this strategic acquisition, which aligns with our mission to increase access to advanced fertility care.” He added that Family Beginnings, led by Dr. James Donahue, brings a strong clinical reputation and a commitment to offering cost-effective fertility solutions.
Financial Overview of the Transaction
INVO will acquire the non-clinical assets of Family Beginnings through INVO Centers LLC, a wholly owned subsidiary, for a total purchase price of $750,000. The financial structure includes:
- $350,000 paid in cash at closing (subject to a holdback of $150,000)
- $400,000 in preferred stock designated as Series D Non-Voting Convertible Preferred Stock
Additionally, Dr. Donahue will continue to oversee the clinic's operations under a three-year leadership agreement.
About Family Beginnings
Founded in the late 1990s, Family Beginnings has successfully catered to thousands of patients across Indiana and neighboring states. The clinic is acclaimed for its patient-centered care model and high success rates. It offers a comprehensive range of reproductive services, including:
- In vitro fertilization (IVF)
- Intravaginal culture (IVC) using the INVOcell device
- Intrauterine insemination (IUI)
- Third-party reproduction services
- Fertility preservation
- Advanced diagnostic testing
- Comprehensive patient education and support programs
About INVO Fertility
INVO Fertility is focused on expanding access to assisted reproductive technology (ART) care. The company's strategy emphasizes building, acquiring, and operating fertility clinics, with a focus on the innovative INVOcell procedure. Currently, INVO operates two INVO Centers and one IVF clinic in the United States while engaging in the sale and distribution of INVOcell to third-party clinics.
INVOcell is a groundbreaking medical device, allowing fertilization and early embryo development to occur in vivo within a woman's body, promising a more connected, intimate, and affordable patient experience compared to conventional ART treatments.
Forward-Looking Statements
This announcement contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The company invokes the protections of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause actual results to differ materially from the anticipated outcomes.
Contact Information
For further inquiries, contact:
- Steve Shum, CEO
INVO Fertility, Inc.
Phone: 978-878-9505
Email: sshum@invofertility.com - Investor Relations
Lytham Partners, LLC
Robert Blum
Phone: 602-889-9700
Email: INVO@lythampartners.com